卡博替尼片 | China Drugs ListCabozantinib tablets | China Drugs List
本页为公开参考信息，不构成医疗建议、处方或药品供应要约。请向持证专业人士确认当前批准情况、可获得性及适用性。
其他
- 商品名
- Cabometyx
- 企业
- Ipsen Pharma (欧盟上市许可持有人)Ipsen Pharma (EU authorization holder)
- 药品类型
- 化学药Chemical medicine
- 治疗领域
- 肿瘤科Oncology
- 公开来源记录的适应症
- 欧盟：用于成人晚期肾细胞癌，可在靶向VEGF治疗后单药使用，或单药一线用于中/高危疾病，也可一线与纳武利尤单抗联合。还用于索拉非尼治疗后的肝细胞癌；全身治疗后、放射性碘无效或不适合时的进展性局部晚期或转移性分化型甲状腺癌；以及至少一种生长抑素类似物以外的全身治疗后进展的不可切除或转移性高分化胰腺或胰腺外神经内分泌肿瘤。EU: Advanced renal cell carcinoma in adults, alone after VEGF-targeted therapy or first line for intermediate/poor-risk disease, or first line with nivolumab. Also hepatocellular carcinoma after sorafenib; progressive locally advanced or metastatic differentiated thyroid cancer after systemic therapy when radioiodine is ineffective or unsuitable; and unresectable or metastatic well-differentiated pancreatic or extra-pancreatic neuroendocrine tumors progressing after at least one systemic therapy other than somatostatin analogues.
- 适应症来源与口径
- 欧盟药品特征概要（SmPC） 查阅于 2026-11-02； 当前链接版本. 部分境外适应症；不确立中国批准范围。EU SmPC accessed 2026-11-02; current linked revision. Selected overseas indications; does not establish the Chinese approved scope.
- 说明书信息局限
- 已链接境外官方处方资料；尚未核实完整的现行中国说明书。Overseas official prescribing information linked; a complete current Chinese label has not been verified.
- 中国可获得性状态
- 本次导入未独立核实中国批准、当地批准适应症及当前供应情况。Chinese approval, locally approved indications and current availability have not been independently verified in this import.
- 海外状态
- 请参阅所链接的境外监管机构或厂商证据。批准及适应症因司法辖区而异；尚未确认当前供应情况。See the linked overseas regulator / manufacturer evidence. Approval and indications are jurisdiction-specific; current supply is not established.
- 医保分类
- 尚未核实Not yet verified
- 医保版本
- 中国国家医保信息待核实Chinese national insurance review pending
- 医保核查说明
- 本次新增记录尚未确定报销资格；缺少信息不代表未被纳入。No reimbursement determination was made for this addition; missing information is not proof of exclusion.
来源
- https://www.ema.europa.eu/en/documents/product-information/cabometyx-epar-product-information_en.pdf
- Cabometyx——官方处方资料Cabometyx — official prescribing information
Official prescribing information · EU SmPC accessed 2026-11-02; current linked revision
已核查英文一手来源。此证据描述所引用的境外司法辖区情况，不能核实中国批准、适应症、报销或在售情况。English primary source reviewed. This evidence describes the cited overseas jurisdiction and does not verify Chinese approval, indications, reimbursement or market availability.
证据核查日期：